Primary Prevention of Sudden Cardiac Death: The Time of Your Life

Circulation

Volumn 109, Issue 9, 2004, Pages 1073-1075

  Prystowsky, Eric N ^a  

^a Care Group   (United States)

Author keywords

Death, sudden; Electrophysiology; Focused Perspectives; Prevention; Risk factors

Indexed keywords

AMIODARONE; ANTIARRHYTHMIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO;

CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DEFIBRILLATOR; HEART ARRHYTHMIA; HEART DEATH; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEART VENTRICLE TACHYCARDIA; HIGH RISK PATIENT; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MEDICAID; MEDICARE; MULTICENTER STUDY; PRIORITY JOURNAL; REIMBURSEMENT; REVIEW; RISK BENEFIT ANALYSIS; RISK FACTOR; SUDDEN DEATH; SURVIVAL RATE; TREATMENT OUTCOME;

ANTI-ARRHYTHMIA AGENTS; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HUMANS; MULTICENTER STUDIES; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; SURVIVAL ANALYSIS;

EID: 1542409918     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000121314.13795.F1     Document Type: Review

References (20)

1. State-specific mortality from sudden cardiac death-United States, 1999. CDC MMWR. 2002;57:123-126.
2. Cannom DS, Prystowsky EN. Management of ventricular arrhythmias: detection, drugs, and devices. JAMA. 1999;281:172-179.
3. Caffrey SL, Willoughby PJ, Pepe PE, et al. Public use of automated external defibrillators. N Engl J Med. 2002;347:1242-1247.
4. Beta-Blocker Heart Attack Trial Research Group. A randomized trial of propranolol in patients with acute myocardial infarction. JAMA. 1982;247:1707-1714.
5. Kober L, Trop-Pederson C, Carlsen JE, et al, for the Trandolapril Cardiac Evaluation (TRACE) Study Group. A clinical trial of the ACE inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med. 1995;333:1670-1676.
6. The Cardiac Arrhythmia Suppression Trial (CAST) Investigators. Preliminary report: effect of encainide and flecainide on mortality in a randomized trial of arrhythmia suppression after myocardial infarction. N Engl J Med. 1989;321:406-412.
7. The Cardiac Arrhythmia Suppression Trial II Investigators. Effect of the antiarrhythmic agent moricizine on survival after myocardial infarction. N Engl J Med. 1992;327:227-233.
8. Julian DG, Camm AJ, Frangin G, et al. Randomised trial of effect of amiodarone on mortality in patients with left ventricular dysfunction after recent myocardial infarction. Lancet. 1997;349:667-674.
9. Cairns JA, Conolly SJ, Roberts R, et al. Randomised trial of outcome after myocardial infarction in patients with frequent or repetitive ventricular premature depolarisations. Lancet. 1997;349:675-682.
10. Buxton AE, Lee KL, Fisher JD, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. A randomized study of the prevention of sudden death in patients with coronary artery disease. N Engl J Med. 1999;341:1882-1890.
11. Moss AJ, Hall WJ, Cannom DS, et al, for the Multicenter Automatic Defibrillator Implantation Trial Investigators. Improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335:1933-1940.
12. Prystowsky EN. Screening and therapy for patients with nonsustained ventricular tachycardia. Am J Cardiol. 2000;86(suppl):34K-39K.
13. Bigger JT, for the Coronary Artery Bypass Graft (CABG) Patch Trial Investigators. Prophylactic use of implanted cardiac defibrillators in patients at high risk for ventricular arrhythmias after coronary-artery bypass graft surgery. N Engl J Med. 1997;337:1569-1575.
14. Moss AJ, Zareba W, Hall WJ, et al, for the Multicenter Automatic Defibrillator Implantation Trial II Investigators. Prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346:877-883.
15. Wilber DJ, Zareba W, Hall WJ, et al. Time dependence of mortality risk and defibrillator benefit after myocardial infarction. Circulation. 2004;109:1082-1084.
16. Coromilas J, Buxton AE, Hafley G, et al, for the MUSTT Investigators. How soon after MI should patients with MI and LV dysfunction be screened for NSVT and have electrophysiologic studies done? Circulation. 2001;104:II-784.
17. Buxton AE, Lee KL, DiCarlo L, et al, for the Multicenter Unsustained Tachycardia Trial Investigators. Electrophysiologic testing to identify patients with coronary artery disease who are at risk for sudden death. N Engl J Med. 2000;342:1937-1945.
18. Gregoratos G, Abrams J, Epstein AE, et al. ACC/AHA/NASPE 2002 Guideline update for implantation of cardiac pacemakers and antiarrhythmia devices: summary article. Circulation. 2002;106:2145-2161.
19. Pires LA, Lehmann MH, Buxton AE, et al. Differences in inducibility and prognosis of in-hospital versus out-of-hospital identified nonsustained ventricular tachycardia in patients with coronary artery disease: clinical and trial design implications. J Am Coll Cardiol. 2001;38:1156-1162.
20. Mark DB, Hlatky MA, Califf RM, et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. N Engl J Med. 1995;332:1418-1424.